Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2007, for Spherix Incorporated (Note: The input metadata lists "Dominari Holdings Inc.", but the filing text explicitly identifies the registrant as Spherix Incorporated). The Company operates two principal segments: BioSpherix, focused on biotechnology products (specifically Naturlose for Type 2 diabetes), and InfoSpherix, a government reservation services provider. On June 25, 2007, Spherix signed a definitive agreement to sell the InfoSpherix subsidiary, classifying its operations as discontinued.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2007 | Six Months Ended June 30, 2007 |
|---|---|---|
| Revenue (Continuing Ops) | $3,769 | $4,019 |
| Revenue (Discontinued Ops) | $6,490,000 | $11,837,000 |
| Net Loss (Continuing Ops) | $(1,900,920) | $(3,940,898) |
| Net Income (Discontinued Ops) | $155,261 | $(95,282) |
| Total Net Loss | $(1,745,659) | $(4,036,180) |
| Cash and Equivalents (End of Period) | $7,103,936 (Continuing) + $1,091,000 (Discontinued) | |
| Working Capital | $7.8 million (as of June 30, 2007) | |
| Debt | No outstanding borrowings on line of credit; minimal capital lease obligations. |
Material Changes vs. Prior Period
- Revenue Decline in Discontinued Ops: InfoSpherix revenue decreased 14% ($1.1M) for the quarter and 12% ($1.7M) for the six months compared to 2006. This is primarily due to the conclusion of the National Park Service contract on January 23, 2007, which previously contributed ~$4.0M annually.
- Increased Operating Expenses: Selling, general, and administrative (SG&A) expenses for continuing operations increased by $386,000 (quarter) and $494,000 (six months) year-over-year. Drivers included a $150,000 CEO bonus, $120,000 in accounting costs for FIN 48 implementation, and investment banking fees.
- R&D Surge: Research and development expenses for continuing operations jumped significantly (from $176,988 to $985,937 for the quarter) due to the initiation of the Phase 3 clinical trial for Naturlose in April 2007.
- Cash Flow: Net cash used in operating activities for continuing operations was $3.6 million for the six months ended June 30, 2007, compared to $1.4 million used in the prior year period, driven by clinical trial costs.
Guidance, Outlook, and Risks
- Strategic Shift: The Company intends to focus exclusively on BioSpherix following the sale of InfoSpherix. Proceeds from the sale (agreed at $17 million total: $15M at closing, $2M escrow) are intended to fund the BioSpherix Phase 3 trial.
- Clinical Trial Outlook: The Phase 3 trial for Naturlose (Type 2 diabetes) began in April 2007. Testing is scheduled to finish in mid-2009. FDA approval is not expected before mid-to-late 2010. The Company expects to spend up to $5 million on R&D over the next year.
- Contingencies: The sale of InfoSpherix is subject to shareholder approval at the August 15, 2007 annual meeting. If the sale fails, the Company must reassess the continuation of the clinical trials given the increased costs.
- Lease Obligations: InfoSpherix signed new leases for Frostburg and Clarksburg, MD. Spherix will pay a $475,000 termination fee for its Beltsville facility upon the completion of the sale.
- Risk Factors: Risks include the failure of the Phase 3 trial, inability to secure additional capital if the InfoSpherix sale is not completed, and the loss of the National Park Service revenue stream.
Investor Verification Checklist
- Verify the status of the shareholder vote for the InfoSpherix sale scheduled for August 15, 2007.
- Confirm the exact cash proceeds expected from the InfoSpherix sale and any tangible net asset clauses that might limit cash distribution.
- Monitor the progress and interim results of the Naturlose Phase 3 clinical trial, specifically regarding patient recruitment and safety data.
- Review the Company's cash burn rate relative to the $5 million projected R&D spend for the coming year.
- Check for updates on the anti-plaque clinical trial results expected later in 2007.